NORTHVALE, N.J., May 16, 2017 /PRNewswire/ -- Abon Pharmaceuticals, LLC, a specialty pharmaceutical company, today announcedthat it has received final approval from the FDA for its Abbreviated New Drug Application (ANDA) for Clofarabine Injection, 20 mg/20 mL, Single-use Vial. Clofarabine Injection is a generic equivalent of Genzyme's CLOLAR® Injection, a prescription medicine
About Abon Pharmaceuticals, LLC.Abon Pharmaceuticals, LLC is a specialty pharmaceutical company that emphasizes science and technology in the development of generic and proprietary products with high formulation barriers. Abon has filed multiple patent applications for drug delivery technologies. To date, six products developed at Abon, have been filed with FDA. This is the third FDA approval of product developed by Abon team and the first approval of an Abon ANDA product.
Contact: Salah Ahmed, 845-304-3493, [email protected]
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/abon-received-approval-from-the-us-fda-for-clofarabine-injection-300458833.html
SOURCE Abon Pharmaceuticals, LLC
Subscribe to our Free Newsletters!
Routes of drug administration play a major role in a medical treatment. Selecting a right route of ...
Spinal anesthesia and epidural anesthesia are types of regional anesthesia in which when a drug is ...
Colorectal cancer is a cancer that starts in the colon or the rectum. Colo-rectal cancer is the ...View All